Evidence map›Paper›PMID 41040380›Full record

ArticlebioRxiv : the preprint server for biology2025

Multiple Epigenetic Mechanisms Functionally Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors.

James P Madigan, Stephen G Andrews, Rivka B Farrell, Steven D Forsythe, Rupali Sharma, Michele Ceribelli, Craig J Thomas, Kimia N Shamsian, Shinjen Lin, Ken Chih-Chien Cheng and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

James P MadiganNeuroendocrine Cancer Therapy Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892.ORCID 0000-0002-0503-3704
Stephen G AndrewsNeuroendocrine Cancer Therapy Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892.ORCID 0009-0006-4614-2743
Rivka B FarrellNeuroendocrine Cancer Therapy Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892.
Steven D ForsytheNeuroendocrine Cancer Therapy Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892.
Rupali SharmaNeuroendocrine Cancer Therapy Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892.
Michele CeribelliPrecision Therapeutics and Translational Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.ORCID 0000-0001-9857-9521
Craig J ThomasPrecision Therapeutics and Translational Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.ORCID 0000-0001-9386-9001
Kimia N ShamsianFunctional Genomics Laboratory, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
Shinjen LinFunctional Genomics Laboratory, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
Ken Chih-Chien ChengFunctional Genomics Laboratory, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.ORCID 0000-0001-5764-0648
Samira M SadowskiNeuroendocrine Cancer Therapy Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892.ORCID 0000-0002-7538-9431

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic neuroendocrine tumors (PNETs) are a rare and understudied set of cancers, with increasing incidence. Neuroendocrine tumors are unique in the fact that they express high levels of the somatostatin receptor type 2 (SSTR2), which represents a target for both tumor imaging and therapeutics. PNET grade inversely correlates with SSTR2 tumor staining and higher tumor grade is associated with poor patient prognosis. With no known mutations, SSTR2 expression is believed to be lost through aberrant epigenetic mechanisms. Enhanced knowledge of the epigenetic biology and players controlling SSTR2 expression may allow for identification of novel PNET imaging and treatment modalities. Through in-depth studies, we found that the specific

Identifiers

PMID41040380
PMCPMC12485957

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.